Medtronic plc Quarterly Report for Q1 Ended Jul 26, 2019

Summary

Medtronic plc (MDT) reported its first-quarter fiscal year 2020 results, ending July 26, 2019. The company generated net sales of $7.49 billion, a modest 1% increase year-over-year. While overall revenue saw slight growth, net income attributable to Medtronic declined by 20% to $864 million, translating to a diluted EPS of $0.64, down from $0.79 in the prior year period. This decline in profitability was largely attributed to a significant increase in interest expense driven by debt extinguishment activities, specifically the tender and early redemption of senior notes. Despite the net income dip, Medtronic demonstrated solid operational cash flow generation, with $1.51 billion in cash from operations and $1.21 billion in free cash flow, underscoring the underlying strength of its business operations.

Key Highlights

• 1Net sales increased by 1% to $7.49 billion, driven by growth in Minimally Invasive Therapies and Restorative Therapies groups, alongside emerging market strength.
• 2Net income attributable to Medtronic decreased by 20% to $864 million, and diluted EPS fell to $0.64 from $0.79.
• 3A significant increase in interest expense, primarily due to $413 million in charges from the tender and early redemption of senior notes, impacted profitability.
• 4Operating cash flow remained strong at $1.51 billion, with free cash flow at $1.21 billion.
• 5The company repurchased approximately 3.3 million shares for $328 million during the quarter, with $6.9 billion remaining under its authorized share repurchase program.
• 6Restructuring charges related to the Enterprise Excellence Program were $136 million for the quarter.
• 7Emerging market sales grew 8%, indicating continued success in Medtronic's globalization strategy.

Frequently Asked Questions